Veterinary Clinical Reference

Look up any drug or condition.

Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.

140 evergreen hubsCited at every claimContinuously updatedFree for verified vets
CanineAug 6, 2026

Salt Toxicosis and Hypernatraemia in Dogs: A Clinical Reference

Salt toxicosis kills through correction, not concentration. Exposure sources, the sodium thresholds that matter, free water deficit, and the maximum safe correction rate for acute versus chronic hypernatraemia in dogs.

Read →
CanineJul 31, 2026

Lead Toxicosis in Dogs: Diagnosis and Chelation Therapy

An ER/toxicology reference for lead poisoning in dogs (cats noted): sources, the combined GI-neurologic presentation, basophilic stippling and nRBCs, whole-blood lead thresholds, radiography, and the stabilize-remove GI lead-chelate sequence with exact CaEDTA, succimer, and D-penicillamine doses.

Read →
CanineJul 30, 2026

Zinc Toxicosis in Dogs: Sources, Hemolysis, Diagnosis, and Treatment

Canine zinc toxicosis causes intravascular hemolysis, hemoglobinuria, and multi-organ injury, usually from a swallowed post-1982 penny or galvanized metal. A clinical reference on zinc sources, the royal-blue-top tube pitfall, source removal, and the chelation debate.

Read →
CanineJul 27, 2026

Selegiline (Anipryl / L-deprenyl) for Canine Cognitive Dysfunction

A DVM clinical reference on selegiline (Anipryl) for canine cognitive dysfunction syndrome: the labeled 0.5–1.0 mg/kg PO q24h dose, MAO-B mechanism, realistic open-label efficacy, adverse effects, and the load-bearing serotonin-syndrome interactions with SSRIs, TCAs, trazodone, tramadol, and amitraz.

Read →
CanineJul 13, 2026

Sileo (Dexmedetomidine Oromucosal Gel) for Canine Noise Aversion: Dosing, Efficacy, and Safety

Sileo (dexmedetomidine oromucosal gel) is the first and only FDA-approved treatment for canine noise aversion — an alpha-2 agonist absorbed transmucosally, dosed by weight as syringe "dots" and given shortly before or at the onset of an anticipated noise event. This hub covers label dosing, the pivotal RCT, adverse effects, contraindications, and where it sits against trazodone, clonidine, tasipimidine, and daily SSRIs.

Read →
CanineJul 13, 2026

Clonidine for Dogs: Off-Label Alpha-2 Agonist for Noise Aversion, Storm Phobia, and Situational Anxiety

Clonidine is a human alpha-2 adrenergic agonist used off-label in dogs as a short-acting, event-based adjunct for situational fear and anxiety — noise aversion, storm phobia, separation-related distress, fear reactivity, and vet-visit anxiety — layered on a daily SSRI or TCA plus behavior modification rather than run as standalone monotherapy. This hub summarizes the off-label dosing (~0.01–0.05 mg/kg PO), the limited open-label efficacy evidence, adverse effects, contraindications and interactions, and where clonidine sits relative to the FDA-approved event drug dexmedetomidine oromucosal gel (Sileo), trazodone, and gabapentin.

Read →
CanineJul 11, 2026

Trazodone for Dogs: Situational Anxiety and Post-Op Confinement Dosing

A clinical reference for prescribing trazodone in dogs: SARI mechanism, off-label status, situational and post-operative confinement dosing, onset, adverse effects, and serotonin syndrome risk with concurrent SSRIs and MAOIs.

Read →
CanineJul 11, 2026

Fluoxetine (Reconcile) for Canine Behavior Disorders

Clinical reference on fluoxetine (Reconcile/Prozac) for dogs: FDA-approved separation-anxiety indication, 1-2 mg/kg dosing, 4-6 week onset, adverse effects, and the MAOI/amitraz and serotonin-syndrome interactions every prescriber must screen for.

Read →
CanineJul 10, 2026

Methylxanthine (Chocolate & Caffeine) Toxicosis in Dogs

ER reference for canine methylxanthine (chocolate/caffeine) toxicosis: theobromine/caffeine MOA and kinetics, mg/kg dose thresholds, chocolate-type ranking, decontamination, and symptomatic management of tachyarrhythmia, seizures, and hyperthermia.

Read →
CanineJul 10, 2026

Grape & Raisin Nephrotoxicosis in Dogs: AKI Management

Clinical reference on grape, raisin, and tamarind nephrotoxicosis in dogs: the idiosyncratic (no safe-dose) nature, the 2022 tartaric-acid hypothesis, the biphasic GI-then-AKI timeline, decontamination, fluid diuresis with serial renal-value monitoring, and prognosis by oliguric status.

Read →
CanineJul 9, 2026

Anticoagulant Rodenticide Toxicosis in Dogs: Clinical Management

A DVM's clinical reference for anticoagulant rodenticide toxicosis in dogs: mechanism, delayed 3-5 day presentation, PT as the earliest marker, vitamin K1 antidotal dosing and duration by generation, plasma for active bleeding, and the recheck-PT-after-stopping rule.

Read →
CanineJul 8, 2026

Xylitol Toxicosis in Dogs: Clinical Management

A DVM reference for xylitol toxicosis in dogs: hypoglycemia at ~0.1 g/kg and hepatic necrosis at ~0.5 g/kg, delayed onset, why activated charcoal fails, and dextrose plus hepatoprotectant protocols with monitoring intervals and prognosis.

Read →